GABA receptor: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
Line 13: Line 13:
GABAB receptors are targeted for a number of treatments in the clinical setting of neurodegenerative and pathophysiolocial disorders including epilepsy, spasticity, chronic pain, anxiety, depression, schizophrenia, cognitive function, gastro-esophageal reflux and drug dependence and addiction (Kerr 2005).
GABAB receptors are targeted for a number of treatments in the clinical setting of neurodegenerative and pathophysiolocial disorders including epilepsy, spasticity, chronic pain, anxiety, depression, schizophrenia, cognitive function, gastro-esophageal reflux and drug dependence and addiction (Kerr 2005).


There is increasing evidence that links schizophrenia directly to GABAB receptor deficits. GABBR1, the gene associated with the expression of the GABAB1 receptor was found to have a high amount of methylation in receptors tested for patients with schizophrenia (Citrine et al. 2009). The receptor 1 gene is on chromosome 6 where the locus is susceptible for multiple sclerosis, epilepsy, and schizophrenia (Sigma Aldrich). Presynaptic dopaminergic terminals (i.e. neuronal terminals that secrete dopamine) have GABAB receptors that are involved in the release of dopamine along with modulation of glutaminergic regulation of dopamine (Citrome et al. 2009).   
There is increasing evidence that links schizophrenia directly to GABAB receptor deficits. GABBR1, the gene associated with the expression of the GABAB1 receptor was found to have a high amount of methylation in receptors tested for patients with schizophrenia (Citrine et al. 2009). The receptor 1 gene is on chromosome 6 where the locus is susceptible for disorders such as multiple sclerosis, epilepsy, and schizophrenia (Sigma Aldrich). Presynaptic dopaminergic terminals (i.e. neuronal terminals that secrete dopamine) have GABAB receptors that are involved in the release of dopamine along with modulation of glutaminergic regulation of dopamine (Citrome et al. 2009).   
   
   
A possible therapeutic approach utilizing GABAB receptors would be for the treatment of substance use disorder (i.e. drug addition). Since the GABAB receptor plays a crucial role in mediating behavioral and molecular effects of drug abuse, the GABAB receptor can be utilized as a potential anti-addictive therapeutic strategy (Flip et. al, 2015). Agonists at GABAB receptors can promote abstinence or decrease and control the reinforcing effects of drugs on the mind (Kerr 2005).
A possible therapeutic approach utilizing GABAB receptors would be for the treatment of substance use disorder (i.e. drug addition). Since the GABAB receptor plays a crucial role in mediating behavioral and molecular effects of drug abuse, the GABAB receptor can be utilized as a potential anti-addictive therapeutic strategy (Flip et. al, 2015). Agonists at GABAB receptors can promote abstinence or decrease and control the reinforcing effects of drugs on the mind (Kerr 2005).